NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Mission Therapeutics

Mission Therapeutics

Private
CambridgeHealthcare & Life Scienceshttps://missiontherapeutics.com/

Last Round

Series D

Extension

Oct 15, 2025

Est. Valuation

$115.4M

Total Funding Raised

$183.55M

Company Overview

Mission Therapeutics is a pharmaceutical research and drug discovery company that develops first-in-class therapeutics targeting deubiquitylating enzymes to treat serious diseases including neurodegenerative conditions, fibrosis, and rare mitochondrial disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

deubiquitylating enzymeDUBParkinson's diseaseDUB inhibitorsmall molecule therapeuticsneurodegenerative diseasedrug discoveryclinical-stage biotechubiquitin-proteasome systembiotech pipelinedrug developmentbiopharmatherapeutic platformdrug candidate

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mission Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Mission Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Mission Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series D ExtensionOct 15, 2025
GrantJul 2, 2024
Series DMar 14, 2024
GrantOct 12, 2021
VC RoundJul 6, 2020
Series C
Feb 2, 2016

Mission Therapeutics Investors

Notable investors and investment history

Mission Therapeutics investors
InvestorRounds
Roche Venture FundSeries A, Series C, Series B, VC Round, Series D Extension, Series D
IP GroupVC Round, Series D, Series D Extension
Parkinson's UKGrant
Woodford Investment ManagementSeries C
Innovate UKGrant
Roche Venture FundSeries B, VC Round, Series D, Series D Extension, Series A, Series C
The Michael J. Fox Foundation for Parkinson's ResearchGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 27, 2025

    Preclinical laboratory operations in Cambridge, UK are closing.

Mission Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mission Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mission Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range11
Year Founded2011
Last FundingOct 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.